CONFERENCE UPDATE: ASCO 2022

PARADIGM: Panitumumab + mFOLFOX6 vs. bevacizumab + mFOLFOX6 as 1L treatment in RAS WT mCRC patients

Glossary: 1L: First-line; AEs: Advaerse events; CI: Confidence interval; DCR: Disease control rate; DoR: Duration of response; ECOG: Eastern Cooperation Oncology Group; ETS: Early tumor shrinkage; HR: Hazard ratio; IV: Intravenous; LE: Life expectancy; mCRC: Metastatic colorectal cancer; OS: Overall survival; PFS: Progression-free survival; PS: Performance status; Q2W: Every 2 weeks; R0: Curative resection; RR: Response rate

Get access to our exclusive articles.